Vaxart, Inc. IPO Filing Research

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows 8-A12B in the pre-IPO sequence.

5,000,000 shares · Gross proceeds $350,000,000

A · Exchange NMS · Ticker VXRT · Use of proceeds working capital

2026-05-08 · 0001437749-26-015961

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

First tracked pre-IPO filing for this issuer.

Gross proceeds $49,772,479

Common Stock, par value $0.0001 per share · Exchange OTCQX · Ticker VXRT · Use of proceeds Proceeds will be used for general corporate purposes. · Underwriters Citizens JMP Securities, LLC, B. Riley Securities, Inc.

2026-05-04 · 0001437749-26-014687

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows 424B5 and marks the registration effective.

2026-04-30 · 9999999995-26-001410

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 424B5 and confirms the priced prospectus.

Price $0.45 · 11,111,111 shares · Gross proceeds $5,000,000

Common Stock · Exchange OTCQX · Ticker VXRT

2025-11-05 · 0001437749-25-033377

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 424B5 and confirms the priced prospectus.

Common Stock, par value $0.0001 per share · Exchange Nasdaq · Ticker VXRT · Underwriters Citizens JMP Securities, LLC, B. Riley Securities, Inc.

2025-03-21 · 0001437749-25-008756

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 424B5 and confirms the priced prospectus.

Common Stock · Ticker VAXR · Underwriters Cantor Fitzgerald & Co., B. Riley Securities, Inc.

2024-10-08 · 0001437749-24-030879

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 424B5 and confirms the priced prospectus.

Price $0.80 · 50,000,000 shares · Gross proceeds $40,000,000

Common Stock · Exchange Nasdaq · Ticker VXRT · Use of proceeds general corporate purposes · Underwriters Oppenheimer & Co.

2024-06-17 · 0001437749-24-020424

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 424B5 and confirms the priced prospectus.

Price $0.65 · 15,384,615 shares · Gross proceeds $10,000,000

Common Stock · Exchange Nasdaq Capital Market · Ticker VXRT

2024-01-18 · 0001437749-24-001566

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 424B5 and confirms the priced prospectus.

Price $0.87 · 16,000,000 shares · Gross proceeds $13,888,000

Common · Exchange Nasdaq Capital Market · Ticker VXRT · Over-allotment 2,400,000 · Use of proceeds Proceeds will be used for general corporate purposes, including reimbursement of offering expenses · Underwriters Cantor

2023-06-08 · 0001437749-23-016979

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 424B5 and confirms the priced prospectus.

Common Stock · Exchange Nasdaq Capital Market · Ticker VXRT · Underwriters Cantor

2023-06-06 · 0001437749-23-016774

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows EFFECT and confirms the priced prospectus.

Gross proceeds $80,444,077

Common Stock · Exchange Nasdaq Capital Market · Ticker VXRT · Use of proceeds general corporate purposes · Underwriters Cantor Fitzgerald & Co., B. Riley Securities, Inc.

2023-05-09 · 0001437749-23-013253

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows 424B5 and marks the registration effective.

2023-05-05 · 9999999995-23-001317

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 424B5 and confirms the priced prospectus.

13,932,490 shares · Gross proceeds $133,400,000

Common Stock · Underwriters Jefferies, Piper Sandler

Vaxart, Inc. terminated its Open Market Sale Agreement with Jefferies LLC and Piper Sandler & Co. on September 13, 2021, after raising $133.4 million through the sale of 13,932,490 shares of common stock since July 2020. The current filing amends the previous prospectus supplement to reflect the termination and discontinuation of sales under the agreement.

2021-09-16 · 0001437749-21-022218

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 424B5 and confirms the priced prospectus.

Gross proceeds $100,000,000

Common Stock · Exchange Nasdaq Capital Market · Ticker VXRT · Use of proceeds General corporate purposes · Underwriters Cantor Fitzgerald & Co., B. Riley Securities, Inc.

Vaxart, Inc. updated its registration to include unsold shares from a prior $250 million offering, terminating the previous sales agreement and engaging new underwriters, Cantor Fitzgerald & Co. and B. Riley Securities, Inc., to sell up to $100 million in common stock. The filing reflects adjustments to the registration fee and continuation of the offering via an at-the-market sales program.

2021-09-16 · 0001437749-21-022232

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 424B5 and confirms the priced prospectus.

Common · Exchange Nasdaq Capital Market · Ticker VXRT · Underwriters Jefferies LLC, Piper Sandler & Co.

Vaxart, Inc. filed a Form 424B5 to register up to $250 million of common stock through an at-the-market offering via sales agents Jefferies LLC and Piper Sandler & Co. This differs from the previous 2020-03-01 filing, which involved a direct offering of 4 million shares and warrants with H.C. Wainwright & Co. as lead placement agent. The current filing emphasizes ongoing sales flexibility and underwriter roles for the sales agents.

2020-10-13 · 0001437749-20-021104

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows EFFECT and confirms the priced prospectus.

Price $2.50 · 4,000,000 shares · Gross proceeds $10,000,000

Common Stock · Exchange Nasdaq Capital Market · Ticker VXRT · Warrants to purchase 2,000,000 shares at $2.50 per share, exercisable immediately, 5-year term. Placement Agent Warrants to purchase 280,000 shares at $3.125 per share. · Use of proceeds General corporate purposes

Vaxart, Inc. is offering 4,000,000 shares of common stock and warrants to purchase up to 2,000,000 shares at a combined price of $2.50 per share and warrant. Placement agent warrants for 280,000 shares are also included. The offering is conducted via a prospectus supplement, with H.C. Wainwright & Co., LLC as the exclusive lead placement agent. The company's common stock is listed on Nasdaq, but warrants have no established trading market. Proceeds are expected to be $9.3M before expenses.

2020-03-02 · 0001437749-20-004082

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows 424B4 and marks the registration effective.

Vaxart, Inc. received SEC effectiveness for its registration statement, enabling the offering of 22,566,667 shares of common stock, 4,100,000 pre-funded warrants, and 26,666,667 common warrants. The offering includes a public price of $0.20 per share, underwriting discounts, and a 30-day option for underwriters to purchase additional shares. The company aims to leverage its oral vaccine platform for infectious diseases and cancer, with no established market for warrants.

2019-10-02 · 9999999995-19-002228

424B4 priced

Final prospectus

Final prospectus filed after pricing with final deal terms.

Follows EFFECT and confirms the priced prospectus.

Price $0.20 · 22,566,667 shares · Gross proceeds $7,590,000

share of our common stock and is accompanied by a common warrant to purchase one share · Exchange Nasdaq Capital Market · Ticker VXRT · Over-allotment 4,000,000 · Pre-Funded Warrants to Purchase 4,100,000 Shares of Common Stock and Common Warrants to Purchase 26,666,667 Shares of Common Stock · Use of proceeds for working capital and other general corporate purposes · Underwriters H.C. Wainwright & Co., Arcadia Securities

Vaxart, Inc. is offering up to 22,566,667 shares of common stock, 4,100,000 pre-funded warrants, and 26,666,667 common warrants. The offering includes a public price of $0.20 per share, with underwriting discounts and commissions totaling $560,000. The company anticipates delivery of securities by September 30, 2019. The offering relates to its oral vaccine development programs, including norovirus, influenza, and RSV candidates. Risks include lack of market for warrants, financial constraints, and regulatory challenges.

2019-09-27 · 0001047469-19-005496

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows FWP and marks the registration effective.

Vaxart, Inc. filed an S-1 registration statement for its IPO, disclosing plans to offer common stock, pre-funded warrants, and warrants. The filing includes results from a Phase 1b trial of its oral bivalent norovirus vaccine, which met primary endpoints with strong immune responses. The company aims to advance to Phase 2 trials in 2020 and targets a $3B+ market for norovirus vaccines. The filing also references a preliminary prospectus and includes forward-looking statements about development and commercialization.

2019-09-26 · 9999999995-19-002185

FWP supplemental

Free writing prospectus

Prospectus supplement or marketing filing that often updates active offering terms.

Follows S-1/A and supplements the active offering with updated prospectus details.

common stock, pre-funded warrants to purchase common stock, and warrants to purchase common stock · Exchange NASDAQ · Ticker VXRT

Vaxart, Inc. issued a press release dated September 25, 2019, detailing positive topline results from its Phase 1b trial of a bivalent norovirus vaccine. The vaccine met primary endpoints for safety and demonstrated robust immunogenicity, with high IgA antibody responses. The company plans to advance to a Phase 2 study in 2020 and highlights the potential $3B+ market opportunity for its oral vaccine platform. The filing relates to a proposed public offering of common stock, pre-funded warrants, and warrants.

2019-09-25 · 0001104659-19-051292

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1/A filing.

Gross proceeds $11,500,000

Common · Pre-funded warrants, common warrants, and representative warrants to purchase common stock

Vaxart, Inc. filed an S-1/A registration statement to amend its IPO offering, focusing on adding exhibits and confirming no substantive changes to the prospectus. The offering includes up to 15,625,000 shares of common stock, pre-funded warrants, and common warrants, with underwriters retaining an option to purchase additional shares. The company highlighted its biotechnology focus and ongoing clinical trials.

2019-09-24 · 0001047469-19-005429

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1 filing.

15,625,000 shares

common · Exchange Nasdaq Capital Market · Ticker VXRT · Over-allotment 2,343,750 · Pre-funded warrants exercisable for one share each at $0.10 and common warrants exercisable immediately for five years · Use of proceeds For general corporate purposes, including working capital and research and development · Underwriters underwriters

Vaxart, Inc. is a clinical-stage biotechnology company developing oral recombinant vaccines using its proprietary platform. The company is offering up to 15,625,000 shares of common stock, pre-funded warrants, and common warrants to raise capital. The offering includes underwriters H.C. Wainwright & Co. and Arcadia Securities. The filing amends previous disclosures, updating registration fees, underwriting terms, and offering details.

2019-09-20 · 0001047469-19-005370

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows EFFECT in the pre-IPO sequence.

share of our common stock and will be accompanied by a common warrant to purchase one share · Exchange Nasdaq Capital Market · Ticker VXRT · Pre-funded warrants, common warrants, and representative warrants to purchase common stock

Vaxart, Inc. is a clinical-stage biotechnology company developing oral recombinant vaccines using its proprietary platform. The company is offering up to shares of common stock, pre-funded warrants, and common warrants to raise capital. The offering includes underwriters H.C. Wainwright & Co. and Brookline Capital Markets. Vaxart's vaccines target infectious diseases like norovirus, influenza, RSV, and HPV-related cancers, with a focus on convenient oral administration. The filing highlights risks related to clinical trial outcomes, regulatory approval, and market competition.

2019-09-11 · 0001047469-19-005145

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows 424B4 and marks the registration effective.

Vaxart, Inc. filed a Notice of Effectiveness for its IPO on April 11, 2019, offering 925,455 shares of common stock and accompanying warrants, along with pre-funded warrants for 8,165,455 shares. The offering includes underwriting discounts, with H.C. Wainwright & Co. as the sole book-runner and CIM Securities, LLC as a manager. The company, a clinical-stage biotech, focuses on oral recombinant vaccines for infectious diseases and cancer, with no revenue generated to date.

2019-04-11 · 9999999995-19-000675

424B4 priced

Final prospectus

Final prospectus filed after pricing with final deal terms.

Follows EFFECT and confirms the priced prospectus.

Price $1.00 · 925,455 shares · Gross proceeds $8,483,456

Common Stock · Exchange Nasdaq Capital Market · Ticker VXRT · Over-allotment 1,363,636 · Pre-funded warrants to purchase 8,165,455 shares and common warrants to purchase 9,090,910 shares · Use of proceeds Proceeds used for company expenses and underwriting discounts · Flags warrants · Underwriters H.C. Wainwright & Co., CIM Securities, LLC

Vaxart, Inc. is offering 925,455 shares of common stock and accompanying warrants, along with pre-funded warrants for 8,165,455 shares. The offering includes underwriting details, with H.C. Wainwright & Co. as the sole book-runner. Proceeds are intended for general corporate purposes. The filing highlights risks related to the lack of a trading market for warrants and the early-stage development of its vaccine candidates.

2019-04-10 · 0001047469-19-002130

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior 424B5 filing.

5,300,000 shares

share of our common stock and will be accompanied by a common warrant to purchase one share · Exchange Nasdaq Capital Market · Ticker VXRT · Over-allotment 795,000 · Shares of common stock and accompanying common warrants, which are immediately separable upon issuance · Pre-funded warrants exercisable for one share at $0.10 per share; common warrants exercisable immediately for one share, expiring in five years. Underwriters receive representative warrants for 7% of shares sold. · Use of proceeds For working capital and general corporate purposes · Underwriters H.C. Wainwright & Co., LLC

Vaxart, Inc. is a clinical-stage biotechnology company developing oral recombinant vaccines using its proprietary platform. The company is offering up to 5,300,000 shares of common stock and associated warrants, with underwriters H.C. Wainwright & Co. and CIM Securities. The filing reflects an amended public offering, contrasting with a prior private placement (424B5) for institutional investors. Key focus areas include norovirus, influenza, RSV, and therapeutic vaccines for HPV-related cancers.

2019-04-08 · 0001047469-19-002040

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows S-1/A and marks the registration effective.

Vaxart, Inc. received effectiveness for its S-1 registration statement on April 8, 2019, enabling the company to proceed with its initial public offering. The filing details an offering of up to 5,300,000 shares of common stock, pre-funded warrants, and common warrants, with underwriters retaining an option to purchase additional shares. The offering includes mechanisms for investors exceeding ownership thresholds, and the registration fee is calculated at $4,151.

2019-04-08 · 9999999995-19-000635

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows EFFECT and confirms the priced prospectus.

Price $2.50 · 1,200,000 shares · Gross proceeds $3,000,000

Common Stock · Exchange Nasdaq Capital Market · Ticker VXRT · Warrants to purchase shares issued to placement agents · Underwriters H.C. Wainwright & Co., LLC, Brookline Capital Markets

Vaxart, Inc. is offering 1,200,000 shares of common stock at $2.50 per share to institutional accredited investors via a prospectus supplement. The filing details the company's clinical-stage focus on oral recombinant vaccines for infectious diseases and cancer, including norovirus, influenza, and HPV. The offering is managed by H.C. Wainwright & Co., LLC as lead placement agent and Brookline Capital Markets as co-placement agent. The company highlights risks related to clinical trial outcomes, regulatory approval, and reliance on third-party collaborators.

2019-03-20 · 0001047469-19-001462

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows S-1/A and marks the registration effective.

Vaxart, Inc. filed a Notice of Effectiveness for its Form S-3 registration statement on March 15, 2019, confirming the effectiveness of its securities offering. The company is offering up to 6,000,000 shares of common stock and pre-funded warrants to purchase shares, with underwriters having an option to purchase additional shares. The offering includes details on pricing, underwriting discounts, and the absence of a public market for the warrants. The filing references risk factors, capitalization, and use of proceeds.

2019-03-15 · 9999999995-19-000441

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1 filing.

6,000,000 shares

Common Stock · Exchange Nasdaq Capital Market · Ticker VXRT · Over-allotment 900,000 · Pre-funded warrants to purchase common stock and representative warrants to purchase common stock · Use of proceeds Working capital, research and development, and other general corporate purposes · Flags warrants · Underwriters H.C. Wainwright & Co., LLC, CIM Securities, LLC

Vaxart, Inc. is conducting an IPO to raise capital through the offering of up to 6,000,000 shares of common stock and related pre-funded warrants. The company, a clinical-stage biotechnology firm, focuses on developing oral recombinant vaccines using its proprietary platform. The offering includes underwriting details, with H.C. Wainwright & Co. as the sole book-running manager and CIM Securities, LLC as a manager. The registration statement reflects updates to the offering structure, including revised pricing assumptions and expanded underwriter roles compared to the initial S-1 filing.

2019-02-20 · 0001047469-19-000571

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows 425 in the pre-IPO sequence.

Gross proceeds $11,500,000

Common Stock, par value $0.10 per share; pre-funded warrants to purchase common stock; representative warrants to purchase common stock · Exchange Nasdaq Capital Market · Ticker VXRT · Pre-funded warrants exercisable for common stock; representative warrants exercisable for common stock · Use of proceeds General corporate purposes · Underwriters H.C. Wainwright & Co., LLC, CIM Securities, LLC

Vaxart, Inc. is a clinical-stage biotechnology company developing oral recombinant vaccines using its proprietary platform. The S-1 filing outlines an IPO offering up to shares of common stock and pre-funded warrants, targeting infectious diseases like norovirus, influenza, and RSV, as well as therapeutic vaccines for HPV-related cancers. The company emphasizes advantages of oral administration, including patient convenience and broader immune responses. The offering includes underwriters H.C. Wainwright & Co. and CIM Securities, LLC.

2019-02-06 · 0001047469-19-000376

425 supplemental

425

Pre-IPO filing captured from the SEC submission timeline.

Follows 425 in the pre-IPO sequence.

Vaxart, Inc. announced a merger update with Aviragen Therapeutics, Inc., highlighting East Hill's support for the transaction. The filing reflects adjustments to the merger terms, including revised ownership percentages post-merger, and emphasizes the strategic alignment between the companies to enhance shareholder value.

2018-02-09 · 0001437749-18-002181

425 supplemental

425

Pre-IPO filing captured from the SEC submission timeline.

Follows 425 in the pre-IPO sequence.

Aviragen Therapeutics, Inc. and Vaxart, Inc. entered into a settlement agreement with the CAS Group to resolve shareholder disputes related to the proposed merger. The CAS Group agreed to support the merger, withdraw proxy solicitations, and refrain from opposing the transaction, facilitating the merger process and shareholder voting on the stock issuance and reverse stock split.

2018-02-09 · 0001437749-18-002183

425 supplemental

425

Pre-IPO filing captured from the SEC submission timeline.

Follows 425 in the pre-IPO sequence.

Vaxart, Inc. and Aviragen Therapeutics, Inc. amended their merger agreement on February 7, 2018, increasing the Parent Valuation from $60 million to $86.47 million. This adjusted the exchange ratio, resulting in Vaxart shareholders owning ~51% and Aviragen shareholders ~49% of post-merger shares. A support agreement with SC Fund Management LLC ensured votes for the merger. The filing also updated proxy statement disclosures, including revised ownership percentages and merger terms.

2018-02-07 · 0001437749-18-001952

425 supplemental

425

Pre-IPO filing captured from the SEC submission timeline.

Follows 425 in the pre-IPO sequence.

The current filing reports the adjournment of Aviragen Therapeutics' special meeting to allow additional time for stockholders to vote on the merger with Vaxart, Inc. The meeting was rescheduled for February 9, 2018, with no change to the record date. The filing emphasizes the ongoing merger process and related risks, including regulatory and shareholder approval uncertainties.

2018-02-06 · 0001437749-18-001781

425 supplemental

425

Pre-IPO filing captured from the SEC submission timeline.

Follows 425 in the pre-IPO sequence.

Aviragen Therapeutics, Inc. issued a press release on January 31, 2018, to support shareholder approval of the proposed merger with Vaxart, Inc. This follows a prior press release on January 26, 2018, responding to a report by Institutional Shareholder Services (ISS). Both filings emphasize forward-looking statements and risks related to the merger's completion.

2018-02-01 · 0001437749-18-001417

425 supplemental

425

Pre-IPO filing captured from the SEC submission timeline.

Follows 425 in the pre-IPO sequence.

Vaxart, Inc. issued a statement supporting the proposed merger with Aviragen Therapeutics, Inc., emphasizing the strategic benefits of combining operations. The merger aims to leverage Vaxart's vaccine development capabilities with Aviragen's antiviral assets, including the BTA074 Phase 2 program for HPV-related condyloma. Vaxart's CEO, Wouter Latour, highlighted the potential for accelerated development of oral vaccines and therapeutic programs, while urging Aviragen shareholders to approve the transaction.

2018-02-01 · 0001437749-18-001425

425 supplemental

425

Pre-IPO filing captured from the SEC submission timeline.

Follows 425 in the pre-IPO sequence.

Vaxart, Inc. announced positive Phase 2 trial results for its oral influenza vaccine, showing a 48% reduction in infection rates compared to placebo, outperforming the market-leading injectable QIV vaccine. The trial, supported by BARDA, highlighted the vaccine's potential for superior efficacy and convenience. The filing also references ongoing merger discussions with Aviragen Therapeutics, Inc., including Vaxart's commitment to Aviragen's BTA074 Phase 2 program for HPV treatment.

2018-02-01 · 0001437749-18-001427

425 supplemental

425

Pre-IPO filing captured from the SEC submission timeline.

Follows 425 in the pre-IPO sequence.

Aviragen Therapeutics, Inc. issued a press release on January 26, 2018, responding to a report by Institutional Shareholder Services (ISS) regarding the proposed merger with Vaxart, Inc. The filing emphasizes the company's position on the merger, highlights forward-looking statements, and references the submission of a registration statement containing a proxy statement and prospectus for the transaction. It also underscores the need for investors to review materials filed with the SEC.

2018-01-26 · 0001437749-18-001223

425 supplemental

425

Pre-IPO filing captured from the SEC submission timeline.

Follows 425 in the pre-IPO sequence.

Aviragen Therapeutics, Inc. responds to a proxy contest related to its proposed merger with Vaxart, Inc., addressing concerns about the merger's valuation, synergies, and corporate governance. The filing highlights the board's decision to explore a shareholder rights plan, clarifies the break-up fee structure, and defends the merger's strategic rationale, including financial stability and operational synergies. It also addresses criticisms of Vaxart's management credibility and clinical development risks.

2018-01-24 · 0001437749-18-001083

425 supplemental

425

Pre-IPO filing captured from the SEC submission timeline.

Follows 425 in the pre-IPO sequence.

Aviragen Therapeutics, Inc. issued a press release on January 24, 2018, urging stockholders to vote in favor of its proposed merger with Vaxart. The filing includes forward-looking statements about the merger's risks and highlights the company's response to criticisms regarding the transaction, including board negotiations, valuation analysis, and synergies. The press release emphasizes the merger's potential benefits and addresses shareholder concerns.

2018-01-24 · 0001437749-18-001089

425 supplemental

425

Pre-IPO filing captured from the SEC submission timeline.

Follows 425 in the pre-IPO sequence.

Aviragen Therapeutics, Inc. is seeking shareholder approval for its proposed merger with Vaxart, Inc., emphasizing the transaction's value creation potential. The Board unanimously recommends voting FOR the merger, citing enhanced financial strength, expanded pipeline, and strategic synergies. The filing highlights the merger's importance, with a special meeting scheduled for February 6, 2018, and underscores the need for shareholder participation.

2018-01-17 · 0001437749-18-000708

425 supplemental

425

Pre-IPO filing captured from the SEC submission timeline.

Follows 425 in the pre-IPO sequence.

Aviragen Therapeutics, Inc. is seeking stockholder approval for a merger with Vaxart, emphasizing that the transaction maximizes value for shareholders. The board unanimously recommends voting 'FOR' the merger, citing potential combined company value of $264 million compared to Aviragen's $23 million market cap. The merger aims to combine Aviragen's antivirals with Vaxart's oral vaccines, with a focus on clinical milestones and financial viability. Shareholders are urged to vote via proxy before the February 6, 2018, special meeting.

2018-01-16 · 0001437749-18-000675

425 supplemental

425

Pre-IPO filing captured from the SEC submission timeline.

Follows 424B3 in the pre-IPO sequence.

Aviragen Therapeutics, Inc. announced the board's recommendation for stockholders to approve the merger with Vaxart, Inc., following the issuance of a press release and an updated investor presentation. The merger involves Aviragen's subsidiary merging with Vaxart, with Vaxart surviving as a subsidiary. The transaction aims to create a clinical-stage pharmaceutical company focused on oral vaccines and antivirals. The press release highlights the board's unanimous support and outlines the exchange ratio for Vaxart shares.

2018-01-12 · 0001437749-18-000555

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows EFFECT and confirms the priced prospectus.

or by Internet to ensure that your share · Exchange Nasdaq Global Market · Ticker VXRT

Vaxart, Inc. is involved in a proposed merger with Aviragen Therapeutics, Inc., where Aviragen will merge into Vaxart, resulting in Aviragen being renamed Vaxart, Inc. The merger aims to create a clinical-stage pharmaceutical company focused on oral recombinant vaccines and antivirals. Shareholders of Vaxart will receive 0.3198 shares of Aviragen common stock per Vaxart share, with the combined company expected to trade on Nasdaq under the symbol VXRT. Stockholder approvals are required for the merger, reverse stock split, and executive compensation proposals.

2018-01-03 · 0001437749-18-000043

S-4/A amended

S-4/A

Pre-IPO filing captured from the SEC submission timeline.

Updates the prior 425 filing.

Price $0.59 · 62,509,974 shares

Common Stock · Exchange NASDAQ · Ticker VXRT · Use of proceeds Merger consideration and related transaction costs

Vaxart, Inc. is involved in a merger with Aviragen Therapeutics, Inc., where Aviragen will merge into Vaxart, with Vaxart surviving as a wholly-owned subsidiary. The merger will result in Aviragen being renamed Vaxart, Inc., and the combined company will focus on oral recombinant vaccines and antivirals. Shareholders of Vaxart will receive Aviragen common stock at an exchange ratio of 0.3198, and Aviragen shareholders will own 40% of the post-merger company. The transaction requires stockholder approvals, including a reverse stock split, and is expected to list on Nasdaq under the symbol VXRT.

2017-12-29 · 0001437749-17-021271

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows S-4/A and marks the registration effective.

Vaxart, Inc. (formerly Aviragen Therapeutics, Inc.) completed a merger transaction, resulting in Aviragen being renamed Vaxart, Inc. The merger involved exchanging Vaxart shares for Aviragen common stock at an estimated ratio of 0.3198, with the combined company focusing on oral vaccines and antivirals. The transaction required shareholder approvals and a reverse stock split, with the combined company expected to list on Nasdaq under the ticker VXRT.

2017-12-29 · 9999999995-18-000015

425 supplemental

425

Pre-IPO filing captured from the SEC submission timeline.

Follows S-4 in the pre-IPO sequence.

The current 425 filing relates to an investor presentation by Aviragen Therapeutics, Inc. and Vaxart, Inc. regarding their proposed merger. The presentation outlines the merger structure, exchange ratio, and regulatory filings, building on the S-4 registration statement from December 2017. Key details include the exchange ratio of 0.3186 shares of Aviragen for each Vaxart share, a reverse stock split, and the intention to list the combined company on Nasdaq. The filing emphasizes forward-looking statements and risks associated with the merger.

2017-12-19 · 0001437749-17-020880

S-4 filed

S-4

Pre-IPO filing captured from the SEC submission timeline.

Follows 425 in the pre-IPO sequence.

58,641,490 shares

Common · Exchange Nasdaq Global Market · Ticker VXRT · Use of proceeds To facilitate the merger and related transactions

Vaxart, Inc. is involved in a proposed merger with Aviragen Therapeutics, Inc., where Aviragen will merge with Vaxart, and the combined company will be renamed Vaxart. The merger involves exchanging Vaxart shares for Aviragen stock at an estimated ratio of 0.3186, with Aviragen shareholders owning 40% and Vaxart shareholders 60% of the post-merger company. The transaction requires stockholder approvals, including a reverse stock split and executive compensation proposals. Aviragen plans to list the combined company on Nasdaq under the symbol VXRT.

2017-12-12 · 0001437749-17-020581

425 supplemental

425

Pre-IPO filing captured from the SEC submission timeline.

Follows 425 in the pre-IPO sequence.

Vaxart, Inc. and Aviragen Therapeutics, Inc. held a joint conference call on October 30, 2017, to discuss their proposed merger. The filing includes a transcript of the call (Exhibit 99.1) and emphasizes forward-looking statements about the merger's risks, including stockholder approval, market price volatility, and regulatory uncertainties. The merger aims to create a combined entity focused on oral vaccines, with Vaxart becoming a subsidiary of Aviragen.

2017-10-31 · 0001437749-17-017970

425 supplemental

425

Pre-IPO filing captured from the SEC submission timeline.

Follows 424B5 in the pre-IPO sequence.

Aviragen Therapeutics, Inc. entered into a merger agreement with Vaxart, Inc., a clinical-stage biotechnology company, to merge Merger Sub into Vaxart, making Vaxart a wholly-owned subsidiary. The merger is structured to qualify as a tax-free reorganization. Post-merger, Aviragen's name will change to Vaxart, and the board will include four Vaxart-designated directors and three independent directors. The exchange ratio ensures Vaxart shareholders own ~60% of the combined entity. The merger requires stockholder approvals and includes a reverse stock split to meet Nasdaq listing requirements. Aviragen also plans to reduce its workforce by six employees, incurring $0.9M–$1.7M in termination costs.

2017-10-30 · 0001437749-17-017778

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows EFFECT and confirms the priced prospectus.

Gross proceeds $25,000,000

Common · Exchange NASDAQ · Ticker BOTA · Use of proceeds general corporate purposes · Underwriters MLV & Co. LLC, FBR Capital Markets & Co.

Vaxart, Inc. (Biota Pharmaceuticals, Inc.) filed a 424B5 prospectus supplement to disclose details of an at-market equity offering through distribution agents MLV & Co. LLC and FBR Capital Markets & Co., authorizing up to $25 million in common stock sales. This follows the July 2015 effectiveness of an S-3 shelf registration, enabling flexible securities offerings.

2015-10-02 · 0001437749-15-018020

424B2 filed

Prospectus supplement

Prospectus supplement that can carry timing details without itself confirming imminent trading.

Follows 424B5 in the pre-IPO sequence.

Common Stock, Preferred Stock, Debt Securities, Warrants, Units · Exchange NASDAQ · Ticker BOTA · Use of proceeds for general corporate purposes

Vaxart, Inc. filed a 424B2 prospectus for a shelf registration of up to $125 million in securities, including common stock, preferred stock, debt, warrants, and units. The filing allows for flexible offerings with terms detailed in future supplements, unlike the previous 424B5 filing, which specified a $24.99 million offering of 5.8 million shares at $4.30 each with Guggenheim Securities as the underwriter.

2015-07-15 · 0001437749-15-013627

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows 424B2 and marks the registration effective.

The filing represents the effectiveness of Biota Pharmaceuticals, Inc.'s S-3 registration statement for potential securities offerings, including common stock, preferred stock, debt securities, warrants, and units, with an aggregate maximum offering price of $125 million. The prospectus provides a general description of offered securities, with specific terms to be detailed in supplements and free writing prospectuses. The company's common stock is listed on NASDAQ under 'BOTA,' with a recent closing price of $2.36 as of July 15, 2015.

2015-07-15 · 9999999995-15-001929

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 424B5 and confirms the priced prospectus.

Price $4.30 · 5,813,900 shares · Gross proceeds $24,999,770

Common · Exchange NASDAQ Global Select Market · Ticker BOTA · Over-allotment 872,085 · Underwriters Guggenheim Securities

Biota Pharmaceuticals, Inc. is finalizing the offering of 5,813,900 shares of common stock at $4.30 per share, with proceeds totaling $23.5 million. The filing includes finalized underwriting terms and delivery details, contrasting with the preliminary nature of the previous filing.

2014-01-10 · 0001437749-14-000476

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows EFFECT and confirms the priced prospectus.

Common · Exchange NASDAQ_GLOBAL_SELECT_MARKET · Ticker BOTA · Use of proceeds Proceeds to be used for general corporate purposes · Underwriters Guggenheim Securities

The current filing is a Form 424B5 prospectus supplement for Biota Pharmaceuticals, Inc., providing details about an offering of common stock under an already effective S-3 registration statement. The filing includes pricing, underwriting terms, and delivery expectations for the shares, with Guggenheim Securities as the underwriter. This follows the previous 'EFFECT' filing that confirmed the S-3 registration's effectiveness in October 2013.

2014-01-09 · 0001437749-14-000417

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows 8-A12B and marks the registration effective.

The filing confirms the effectiveness of Biota Pharmaceuticals, Inc.'s S-3 registration statement, enabling the company to register securities for public offering. The document outlines a Rights Agreement designed to protect the company's net operating loss (NOL) carryforwards by limiting ownership changes that could trigger Section 382 of the IRS Code, which restricts NOL usage. The agreement grants preferred share purchase rights to common stockholders, exercisable under specific conditions related to ownership thresholds.

2013-10-17 · 9999999995-13-002997

8-A12B effective

Exchange Act registration

Registration filed to list the securities under the Exchange Act ahead of trading.

First tracked pre-IPO filing for this issuer.

Nabi Biopharmaceuticals filed an 8-A12B to register preferred stock purchase rights, aiming to protect the company's net operating losses (NOLs) from limitations under Section 382 of the IRS code. The Rights Agreement prevents ownership changes exceeding 4.99% without board approval, ensuring NOLs remain usable to offset future taxes. The rights are exercisable after a specified date and entitle holders to purchase preferred stock at a set price, with potential exchange for common stock under certain conditions.

2011-08-25 · 0001193125-11-232477

Vaxart, Inc.

Filing Timeline

10 comparable deals

Recent News